With a resounding unanimous vote, the U.S. | With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not infringe patents held by the Irish company.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Supreme Court backs generic drugmaker in 'skinny labeling' case
Generic drugmakers gain key victory in ‘skinny label’ patent case
US supreme court backs generic drugmaker over Irish-American firm in patent case
Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case
Supreme Court sides with Hikma in 'skinny label' case
Treatment for millions at stake in 'skinny label' Supreme Court case
Supreme Court backs generic drugmaker in patent case
Will Makary's FDA voucher program survive?
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with…
The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching…
Dublin-based Amarin loses appeal over patent on its cardiovascular drug Vascepa
Court says defendant Amarin Pharma hasn't shown enough harm; remands case to lower court
The Supreme Court has unanimously sided with Hikma Pharmaceuticals and its “skinny label” version of a prescription-strength fish…
The Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. ruling could have a major effect on incentives to invest in research…
